million people affected worldwide

Current Treatments

Psychedelic research currently is in Preclinical

About 30% or one in three of those suffering from depression are dealing with so-called treatment-resistant depression (TRD). The name refers to that these patients have tried at least two treatment options, without success. Psychedelics may offer hope to those suffering from TRD.

This topic is currently a stub, it will be expanded upon in the near future.

Highlighted Institutes

These are the institutes, from companies to universities, who are working on Treatment-Resistant Depression.

Revixia Life Sciences

Revixia Life Sciences is a biotech company developing Salvinorin A (salvia) for substance use disorders (SUD), treatment-resistant depression (TRD), and pain.

Highlighted People

These are some of the best-known people, from researchers to entrepreneurs, working on Treatment-Resistant Depression.

George Goldsmith

George Goldsmith is the CEO, Co-Founder, and Chairman of Compass Pathways, which he has led since July 2016.

Linked Research Papers & Trials

Pro & Business members will be able to see all linked papers and trials directly on this topic page.

This information is still available for you by selecting Treatment-Resistant Depression on the Papers and Trials pages respectively.

See the information directly on this page with a paid membership.